title: Oncogene-induced sensitization to chemotherapy-induced death requires induction as well as deregulation of E2F1.
abstract: The analysis of DNA tumor viruses has provided landmark insights into the molecular pathogenesis of cancer. A paradigm for this field has been the study of the adenoviral E1a protein, which has led to the identification of proteins such as p300, p400, and members of the retinoblastoma family. Through binding Rb family members, E1a causes deregulation of E2F proteins--an event common to most human cancers and a central pathway in which oncogenes, including E1a, sensitize cells to chemotherapy-induced programmed cell death. We report here, however, that E1a not only causes deregulation of E2F, but importantly that it also causes the posttranscriptional upregulation of E2F1 protein levels. This effect is distinct from the deregulation of E2F1, however, as mutants of E2F1 impaired in pRb binding are induced by E1a and E2F1 induction can also be observed in Rb-null cells. Analysis of E1a mutants selectively deficient in cellular protein binding revealed that induction of E2F1 is instead intrinsically linked to p400. Mutants unable to bind p400, despite being able to deregulate E2F1, do not increase E2F1 protein levels and they do not sensitize cells to apoptotic death. These mutants can, however, be complemented by either the knockdown of p400, resulting in the restoration of the ability to induce E2F1, or by the overexpression of E2F1, with both events reenabling sensitization to chemotherapy-induced death. Due to the frequent deregulation of E2F1 in human cancer, these studies reveal potentially important insights into E2F1-mediated chemotherapeutic responses that may aid the development of novel targeted therapies for malignant disease.
authors.affiliation: Tumour Cell Death Laboratory, Beatson Institute for Cancer Research, Glasgow, United Kingdom.
authors.forename: G Vignir
authors.initials: GV
authors.lastname: Helgason
authors.forename: Jim
authors.initials: J
authors.lastname: O'Prey
authors.forename: Kevin M
authors.initials: KM
authors.lastname: Ryan
mesh_terms: D017500:Adenovirus E1A Proteins / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D017209:Apoptosis; D015153:Blotting, Western; D002478:Cells, Cultured; D004265:DNA Helicases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D004317:Doxorubicin / Q000494:pharmacology; D050881:E1A-Associated p300 Protein / Q000235:genetics / Q000378:metabolism*; D050687:E2F1 Transcription Factor / Q000502:physiology*; D004622:Embryo, Mammalian / Q000166:cytology; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D005434:Flow Cytometry; D006801:Humans; D047468:Immunoprecipitation; D051379:Mice; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D055213:Retinal Pigment Epithelium / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D016160:Retinoblastoma Protein / Q000502:physiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D017500:Adenovirus E1A Proteins; D000903:Antibiotics, Antineoplastic; D004268:DNA-Binding Proteins; D050687:E2F1 Transcription Factor; D012333:RNA, Messenger; D016160:Retinoblastoma Protein; D004317:Doxorubicin; D050881:E1A-Associated p300 Protein; D004265:DNA Helicases; C498558:EP400 protein, human
references.citation: Nature. 1983 Aug 18-24;304(5927):602-6
references.pmid: 6308473
references.citation: Cell. 2001 Aug 10;106(3):297-307
references.pmid: 11509179
references.citation: Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12094-9
references.pmid: 9342368
references.citation: Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6103-8
references.pmid: 18413597
references.citation: Cell. 1990 Aug 24;62(4):659-69
references.pmid: 2143697
references.citation: Oncogene. 2008 Jul 10;27(30):4172-9
references.pmid: 18345030
references.citation: Cell. 2000 Aug 18;102(4):463-73
references.pmid: 10966108
references.citation: Virology. 2009 Feb 20;384(2):256-9
references.pmid: 19136134
references.citation: Cell Death Differ. 2007 Jun;14(6):1071-9
references.pmid: 17304243
references.citation: Clin Cancer Res. 2001 Nov;7(11):3590-7
references.pmid: 11705881
references.citation: Cancer Cell. 2002 Nov;2(5):401-13
references.pmid: 12450795
references.citation: J Biol Chem. 2005 Jun 10;280(23):21915-23
references.pmid: 15741165
references.citation: Mol Cell Biol. 2004 May;24(10):4546-56
references.pmid: 15121871
references.citation: Nat Rev Mol Cell Biol. 2002 Jun;3(6):441-52
references.pmid: 12042766
references.citation: Cell. 2006 Jul 14;126(1):121-34
references.pmid: 16839881
references.citation: J Virol. 1994 Aug;68(8):5027-35
references.pmid: 8035503
references.citation: J Virol. 2008 Jun;82(12):5933-9
references.pmid: 18385238
references.citation: Nature. 1991 Jun 6;351(6326):494-7
references.pmid: 1710781
references.citation: Oncogene. 2006 Sep 14;25(41):5656-63
references.pmid: 16652153
references.citation: Mol Cell Biol. 1995 Dec;15(12):6535-44
references.pmid: 8524218
references.citation: Nature. 1988 Jul 14;334(6178):124-9
references.pmid: 2968522
references.citation: J Clin Invest. 2007 Apr;117(4):1008-18
references.pmid: 17347683
references.citation: Cell Cycle. 2009 Jul 15;8(14):2260-5
references.pmid: 19556885
references.citation: Cancer Res. 2009 Jan 1;69(1):6-9
references.pmid: 19117980
references.citation: Cell. 1991 Jun 14;65(6):1053-61
references.pmid: 1828392
references.citation: Eur J Histochem. 1993;37(4):381-90
references.pmid: 7510545
references.citation: Cell Cycle. 2006 Apr;5(8):801-3
references.pmid: 16582589
references.citation: J Virol. 1994 Apr;68(4):2206-14
references.pmid: 8139005
references.citation: Nature. 2005 Jun 9;435(7043):839-43
references.pmid: 15944709
references.citation: Nat Rev Mol Cell Biol. 2002 Jan;3(1):11-20
references.pmid: 11823794
references.citation: Cell Death Differ. 2004 Feb;11(2):137-42
references.pmid: 14526389